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Abstract
Advanced urothelial carcinoma (UC) has a poor prognosis and new treatments are needed. In our study,
multiplatform molecular proﬁling of UC identiﬁed unconventional treatment options in most cases. Different
molecular proﬁles are exhibited between bladder and nonbladder UCs.
Background: Inﬁltrating UC represents the second most common genitourinary malignancy. Advanced UC has a poor
prognosis and new treatments are needed. Molecular proﬁling of UC might identify biomarkers associated with tar-
geted therapies or chemotherapeutics, providing physicians with new treatment options. Materials and Methods:
Five hundred thirty-seven cases of locally advanced or metastatic UC of the bladder, 74 nonbladder, and 55 non-
urothelial bladder cancers were proﬁled using mutation analysis, in situ hybridization, and immunohistochemistry
assays for biomarkers predictive of therapy response. Results: Molecular proﬁling of UC showed high overexpression
of topoisomerase 2a, common phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha and/or phos-
ophatase and tensin homolog (PTEN) alterations in nonbladder (27%) and bladder UC (21%), and rare gene mutations
across subtypes. Compared with nonbladder, bladder UC consistently exhibited more frequent abnormal protein
expression, including HER2 (10% vs. 3%; P ¼ .04), tyrosine protein c-Kit receptor kinases (11% vs. 5%), c-Met proto-
oncogene, receptor tyrosine kinases (25% vs. 8%), androgen receptor (16% vs. 6%), O(6)-methylguanine-
methyltransferase (63% vs. 43%), ribonucleotide reductase M1 (32% vs. 11%), Serum protein acidic and rich in
cysteine (SPARC) (69% vs. 33%), and topoisomerase 1 (63% vs. 39%). Bladder UC also exhibited increased ampli-
ﬁcation of HER2 (12% vs. 2%; P ¼ .06). Conclusion: Comprehensive molecular proﬁling of UC identiﬁed a large
number of biomarkers aberrations that might direct treatment in conventional chemotherapies and targeted therapies,
not currently recommended in this population. As a group, bladder UC exhibited higher levels of actionable biomarkers,
suggesting that UC from different primary sites and non-UC are driven by different molecular pathways. These dif-
ferences could have clinical implications resulting in different treatment regimens depending on the site of origin of UC.
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Inﬁltrating urothelial carcinoma (UC; “transitional cell carci-
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http://dx.doi.org/10.1016/j.clgc.2014.07.010the most common genitourinary malignancy after prostate,1 and is
the fourth most common cancer in men.2 Most UCs originate in
the bladder but rare cases arise in the urethra, ureter, prostate, or
renal pelvis. Approximately 25% to 30% of the patients with UC
present with muscle-inﬁltrating tumors with substantial potential
for further progression, metastases, and death.3-5
Previous molecular studies have shown that UC is character-
ized by mutations and losses of important cancer genes including
Fibroblast growth factor receptor 3 (FGFR3), ras family small
GTPase proteins (RAS), phosphatidylinositol-4,5-bisphosphate 3-
kinase, catalytic subunit alpha (PIK3CA), retinoblastoma tumor
suppressor protein (RB1), phosophatase and tensin homolog
(PTEN), and tumor suppressor protein p53 (TP53).6-9 FGFR3 and
PIK3CA mutations are more prevalent in low-stage carcinomas,d.
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e38 -whereas TP53 mutations are more common in muscle-inﬁltrating
UC.10 Mutations of epidermal growth factor receptor (EGFR)
and HER2 have been rarely observed,11 but HER2 ampliﬁcation
has been described in a subset of bladder cancer patients.12,13
Neither comprehensive simultaneous analysis of these targeted
pathways nor comparison of nonbladder versus bladder UC has
been performed.
In the present study we investigated a broad panel of the most
common targetable biomarkers in a large series of muscle-inﬁltrative
and metastatic UC to identify treatment options that are not
typically considered in this population. Patients with advanced UC
are still not routinely offered individualized targeted therapeutic
options based on tumor proﬁling14; National Comprehensive
Cancer Network (NCCN) guidelines are limited to traditional
chemo- and nontargeted therapies. The demonstration of the high
frequency identiﬁcation of actionable targets in UC patients’ tumors
might encourage more molecular proﬁling, potentially improving
patient outcomes.
Materials and Methods
Tissue Samples
Test results of consecutive tissue samples (2008-2013) of locally
advanced and/or metastatic UCs submitted to a commercial mo-
lecular proﬁling laboratory (Caris Life Sciences, Phoenix, AZ) were
reviewed. Multiplatform proﬁling included immunohistochemistry
(IHC), in situ hybridization, and sequencing.
Immunohistochemistry
Immunohistochemistry analysis was performed on formalin-ﬁxed
parafﬁn-embedded tumor samples using commercially available
detection kits, automated staining techniques (Benchmark XT,
Ventana, Tucson, AZ; and AutostainerLink 48, Dako, Carpinteria,
CA), antibodies against androgen receptor (AR), topoisomerases 1
and 2a (TOPO1, TOPO2a) (Leica Biosystems, Buffalo Grove, IL);
estrogen receptor (ER), progesterone receptor (PR), MET proto-
oncogene, receptor tyrosine kinase (c-Met, human epidermal
growth factor receptor 2 (HER2) (Ventana, Tucson, AZ); tyrosine
protein c-Kit receptor kinase (c-Kit), epidermal growth factor re-
ceptor (EGFR), phosophatase and tensin homolog (PTEN) (Dako),
O(6)-methylguanine-methyltransferase (MGMT), P-glycoprotein
(PGP), thymidylate synthase TS) (Invitrogen, Grand Island, NY);
transducin-like enhancer of split 3 (TLE3; Santa Cruz, Santa Cruz,
CA); ribonucleotide reductase M1 (RRM1) (Protein Tech, Chi-
cago, IL); Serum protein acidic and rich in cysteine (SPARC,
monoclonal, R&D Systems, Minneapolis, MN; polyclonal, Exal-
pha, Shirley, MA) and tubulin beta-3 chain (TUBB3; Covance,
Madison, WI). Scoring system and cutoffs for all antibodies are
provided in Supplemental Table 1.
In Situ Hybridization
Fluorescent in situ hybridization (FISH) was used for evaluation
of the HER2 (HER2/CEP17 [chromosome 17 centromere] probe),
EGFR (EGFR/CEP7 probe), TOPO2A (TOP2/CEP17 probe), and
c-MET (c-MET/CEP7 probe; Abbott Molecular/Vysis, Abbott Park,
IL). HER2/CEP17 ratio > 2.2 was considered ampliﬁed (based
on guidelines from the College of American Pathology [CAP]/
ASCO [American Society of Clinical Oncologists] 2007). EGFRClinical Genitourinary Cancer February 2015ampliﬁcation was deﬁned as EGFR/CEP7 ratio  2, or  15 EGFR
copies per cell in  10% of analyzed cells. TOPO2A ampliﬁcation
was deﬁned as TOPO2A/CEP17 ratio  2.0 and c-MET was
considered ampliﬁed if  5 c-MET copies were detected on average.
HER2 and c-MET status were evaluated using chromogenic
in situ hybridization (INFORM HER2 Dual ISH DNA Probe
Cocktail; commercially available c-MET and chromosome 7
DIG probe; Ventana). The same scoring system was applied as
for FISH.
Mutational Analysis
Next-Generation Sequencing. Direct sequence analysis was
performed on genomic DNA isolated from formalin-ﬁxed parafﬁn-
embedded tumor samples using the Illumina MiSeq platform
(La Jolla, CA). Speciﬁc regions of 45 genes of the genome were
ampliﬁed using the Illumina TruSeq Amplicon Cancer Hotspot
panel (Supplemental Table 2).
Sanger Sequencing. Mutation analysis using Sanger sequencing
included selected regions of V-raf murine sarcoma viral oncogene
homolog B (BRAF), Kirsten rat sarcoma viral oncogene homolog
(KRAS), c-KIT, EGFR, and PIK3CA genes and was performed using
M13-linked polymerase chain reaction (PCR) primers designed to
amplify targeted sequences. PCR products were bidirectionally
sequenced using the BigDye Terminator v1.1 chemistry (Applied
Biosystems, Grand Island, NY), and analyzed using the 3730 DNA
Analyzer (Applied Biosystems). Sequence traces were analyzed using
Mutation Surveyor software v3.25 (Soft Genetics, San Francisco,
CA).
Statistical Methods
Cohen k was performed to determine the interrater agreement
for 2 raters. The 2-tail Fisher exact test was performed to test
where proportions of positive results were different according to
tumor type (P  .05). JMPv10.0 (SAS Institute Inc, Cary, NC) and
R v2.15 (R Foundation for Statistical Computing, Vienna, Austria)
were used for statistical analysis.
Results
Clinicopathologic Characteristics of the Cohort
Five hundred ninety-two urinary tract carcinomas included 463
cases (87.5%) of bladder UC, 74 cases (12.5%) of nonbladder UC
(renal pelvis, ureter, urachus, urethra), and 55 other histotypes
(27 adenocarcinomas, 17 squamous cell carcinomas, and 11 small
cell carcinomas).
Men constituted most patients (379, 64%) in every histologic
category. The mean age of all patients was 66.3 years. Fifty-nine
percent (273) of bladder UC cases were sampled at the primary
site, and 41% (190) were from metastatic sites (lymph node and
distant metastases). Nonbladder UC cases were similarly distributed
(47 patients [64%] primary vs. 27 patients [36%] metastatic cases).
Proﬁling of the UCs for Clinically Actionable Markers
An immunohistochemical and molecular survey of UC was
performed to evaluate concurrence of predictive biomarkers,
revealing differential overlap of TP53, PIK3CA, and PTEN
(Figure 1). The IHC and sequencing results are summarized
Figure 1 Associations and Frequencies in a Subset of Genes
With Mutations, Copy Number Increases, and
Changes in Protein Expression. Total Cases are
Shown, With Coexisting Associations Indicated
Sherri Z. Millis et al(Tables 1 and 2, and Supplemental Tables 2-4). Most cases
exhibited overexpression of 3 or more proteins and/or DNA mu-
tations and ampliﬁcations, as described herein. No differences in
biomarker expression between primary and metastatic sites (lymph
nodes, distant metastases) were noted.
The EGFR and HER2 Pathway (Anti-EGFR and Anti-
HER2 Therapies)
Epidermal growth factor receptor protein overexpression in
bladder UC was seen in 41 of 53 (77%) cases; EGFR ampliﬁcationTable 1 Comprehensive Immunohistochemical Surveys of Urinary B
Histotype/IHC
Marker (# tested) UC, Bladder, % UC, Nonbladder, % Ad
AR (545) 16.2 6.2a
ER (542) 1.9 1.6
PR (541) 2.6 1.6
c-Kit (387) 10.3 4.8
c-MET (167) 25.2 8.3
EGFR (61) 77.4 50.0
HER2 (559) 10.2 3.1a
MGMTb (542) 62.9 43.3
TLE3 (181) 23.9 11.1
TOPO2a (459) 68.1 71.9
TUBB3b (87) 39.0 23.5
PTEN (543) 63.0 56.7
PGPb (455) 27.2 15.5
RRM1b (513) 32.1 10.8a
SPARC (303) 68.7 33.3a
TOPO1 (493) 63.3 38.7a
TSb (506) 17.0 22.2
Abbreviations: IHC ¼ immunohistochemistry; UC ¼ urothelial carcinoma.
aIndicates signiﬁcantly (P < .05) different expression between bladder UC and other histotypes.
bExpression of the biomarker below the threshold is considered predictive of a positive response towas seen in 44 of 198 (22%) cases. One EGFR ampliﬁed case also
exhibited a novel EGFR mutation (H773dup [kinase domain, exon
20]). A different EGFRmutation was identiﬁed in 1 nonbladder UC
(770D_771NinsG). The frequency of EGFR ampliﬁcation was
greater in HER2-ampliﬁed (6 of 17; 35%) than noneHER2-
ampliﬁed bladder UC (18 of 108; 17%; P ¼ .09). Two of 4 non-
bladder UCs overexpressed EGFR; 3 of 31 had EGFR ampliﬁcation.
In bladder UC, HER2 protein overexpression (score 3þ) was
observed in 45 of 441 cases (10%) and gene ampliﬁcation was seen
in 33 of 284 (12%). Overall, IHC/ISH concordance rate for
HER2 status was 91% (k ¼ 0.589). Only 1 UC case harbored a
HER2 mutation (missense, D769H, kinase domain, exon 19) and a
HER2 ampliﬁcation. HER2 ampliﬁcation was also observed in 1 of
43 nonbladder UCs. In HER2-ampliﬁed bladder UC, additional
genetic alterations such as mutations of PIK3CA were rare (1 of 8);
PTEN and serine/threonine-speciﬁc protein kinase B (AKT1) al-
terations were not observed. Apart from the positive association
with EGFR, no other biomarker showed signiﬁcantly different status
in regard to HER2 ampliﬁcation.
Status of c-MET (Antiec-MET Clinical Trials)
Receptor expression of c-Met was observed in 31 of 123 (25%)
bladder UCs, but c-MET gene ampliﬁcation was found in only 1 of
75 cases. This case also harbored a HER2 ampliﬁcation. In contrast,
nonbladder UC rarely overexpressed c-MET (2 of 24, 8.3%).
Status of c-KIT (Imatinib Therapy)
Expression of c-Kit was seen in 33 of 312 (11%) of the bladder
UCs, nonbladder UCs exhibited a low rate of positivity (2 of 43;
5%). The c-KIT mutation was seen in only 1 bladder UC, a
G565V, pathogenic substitution-missense mutation that has not
been previously reported in bladder UC.ladder Carcinoma Subtypes
enocarcinoma, %
Small-Cell
Carcinoma, %
Squamous Cell
Carcinoma, %
3.8 11.8 9.1
0.0 0.0 27.3a
4.0 17.6a 0.0
11.8 37.5a 0.0
44.4 0.0 0.0
0.0 0.0 100.0
3.8 0.0 0.0
69.2 20.0a 40.0
22.2 0.0 33.3
76.2 92.3 57.1
80.0 80.0 0.0
37.5 25.0 25.0
45.5 7.7 11.1
33.3 62.5a 22.2
19.2a 35.3a 9.1a
32.0a 81.3 44.4
12.5 47.1a 11.1
therapy.
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Table 2 Mutation Frequency Proﬁle of Urothelial Carcinomas
Gene UC, Bladder UC, Nonbladder
APC 2/45 (4.4%) 0/16
BRAF 1/120 (0.8%) 0/24
CDH1 3/47 (6.4%) 0/16
c-KIT 1/78 (1.3%) 0/20
c-MET 1/47 (2.1%) 0/16
EGFR 1/53 (1.9%) 1/19 (5.3%)
ERBB2 1/47 (2.1%) 0/16
FBXW7 2/47 (4.3%) 2/16 (12.5%)
FGFR3 0/21 3/10 (30.0%)a
HNF1A 0/41 1/16 (6.3%)
HRAS 0/42 1/16 (6.3%)
KDR 1/47 (2.1%) 0/16
KRAS 5/135 (3.7%) 0/24
PIK3CA 19/113 (16.8%) 5/22 (22.7%)
PTEN 4/47 (8.5%) 1/16 (6.3%)
RB1 2/46 (4.3%) 0/16
SMAD4 1/47 (2.1%) 0/16
STK11 1/45 (2.2%) 0/16
TP53 23/46 (50.0%) 3/14 (21.4%)a
Abbreviation: UC ¼ urothelial carcinoma.
aSigniﬁcantly higher (P < .05) compared with bladder UC.
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e40 -Expression of PTEN
The loss of PTEN protein expression was observed at a high rate
in bladder (45 of 122), and nonbladder UC (13 of 30). Four of 47
bladder UCs and 1 of 16 nonbladder UCs harbored PTEN muta-
tions. Two of the 4 bladder UC mutations were in the C2 domain,
and 2 were in the phosphatase domain; the nonbladder UC mu-
tation (phosphatase domain) has unknown signiﬁcance.
Status of TOPO1 and TOPO2A (Anthracyclines)
Overexpression of TOPO2a protein was high in nonbladder
UCs (41 of 57; 72%) and bladder UCs (246 of 361; 68%).
Gene ampliﬁcation of TOPO2A was observed in 2 bladder UCs
(4%), of which 1 also exhibited concurrent HER2 ampliﬁcation. In
contrast, TOPO1 was more commonly overexpressed in bladder
UC (24 of 381; 63%) than in nonbladder UC (24 of 62; 39%; P <
.0004).
Steroid Receptors Proﬁle (Antihormonal Therapy)
Androgen receptor was the most frequently expressed (69 of 426;
16%) steroid receptor in bladder UC (51 male, 18 female samples).
ER and PR were overexpressed in 8 of 425 (4 female, 4 male
samples; 2%) and 11 of 424 (7 male, 4 female samples; 3%) of the
cases, respectively. Nonbladder UC exhibited similar positivity rates
for AR, ER, and PR (4 of 65; 6%, 1 of 64; 2%, and 1 of 64; 2%,
respectively).
Mutational Analysis
One hundred ﬁfty-seven cases were sequenced, including 135
bladder UCs and 22 nonbladder UCs. Sixty-three cases were
sequenced using the next-generation sequencing (NGS) panel; 94Clinical Genitourinary Cancer February 2015were sequenced using Sanger sequencing. Mutations were identiﬁed
in 19 genes (Table 2 and Supplemental Table 3). The most
commonly mutated gene was TP53.
Mutations were identiﬁed in 51 bladder UC cases (38%;
Table 2). Thirteen of these cases showed more than 1 mutation
(including multiple mutations in a single gene), with 1 case, a
metastatic UC to the lung, previously treated using adjuvant
chemotherapy, exhibiting mutations in 4 genes (cadherin 1, type 1,
E-cadherin [epithelial] [CDH1], PTEN, PIK3CA, and TP53). Of
the remaining 12 cases, 1 case harbored 3 different mutations
(TP53, PTEN, and RB1), and the remaining 11 cases had 2
mutations.
Common (> 5% rate) single mutations affecting bladder UC
included TP53 (23 of 46; 50%), PIK3CA (19 of 113; 17%), PTEN
(4 of 47; 9%), and CDH1 (3 of 47; 6%). No bladder UC exhibited
an FGFR3 mutation in contrast to the nonbladder UCs (3 of 10;
P ¼ .02). Of note, 2 of 3 nonbladder carcinomas (renal pelvis) with
the FGFR3 mutation represented high-grade, nonmuscle-inﬁltrating
UC and the third case was a high-grade, invasive UC with invasion
into renal sinus fat.
Four UCs of the bladder with PIK3CA mutations also showed
concurrent mutations of PTEN, TP53, and CDH1 (1 case),
TP53 (2 cases), and KRAS (1 case). All were HER2-negative. The
most common PIK3CA mutations were E542K, E545K (helical
domain), and H1074R (kinase domain) mutations present in 14
of 19 (74%) of the cases (Table 2). Adenomatous polyposis
coli gene mutations were identiﬁed in 2 of 45 (4%) of the
bladder cases of which 1 represented a nested variant of inﬁl-
trative bladder UC.
Of the nonbladder cases, mutations were identiﬁed in 10 of
15 cases tested with the NGS panel (69%; Supplemental Table 4).
Multiple gene mutations were detected in 2 nonbladder UCs; both
involved the F-box and WD repeat domain containing 7, E3
ubiquitin protein ligase (FBXW7) gene. Apart from the FGFR3 (3 of
10; 30%) and FBXW7 (2 of 16; 13%), nonbladder UCs showed
patterns of mutations similar to their bladder counterparts (> 5%):
PTEN (1 of 16; 6%), TP53 (3 of 14; 21%), and PIK3CA (5 of 22;
23%). Single cases also harbored Harvey rat sarcoma viral oncogene
homolog and HNF1 homeobox A mutations that were not seen in
UC of the bladder.
BiomarkereDrug Associations
The most common chemotherapeutic drugs associated with the
potential beneﬁt in UC were anthracyclines (overexpression of
TOPO2a in 68% of bladder [246 of 361] and 72% of nonbladder
UCs [41 of 57]). Other commonly associated drugs include
mammalian target of rapamycin (mTOR) inhibitors (PTEN and
PIK3CA alterations), TOPO1 inhibitors, and taxanes (over-
expression of SPARC and TLE3; underexpression of TUBB3). Lack
of potential beneﬁt association was noted when a biomarker did not
reach the threshold for the positive association or when a high
expression of the biomarker led to a lack of potential beneﬁt asso-
ciation (eg, TUBB3 and taxanes, MGMT and temozolomide/
dacarbazine). The biomarker results for each case were associated
with drugs with potential beneﬁt or lack of potential beneﬁt, based
on the published literature. An overview of frequency of drug as-
sociations speciﬁc to the biomarker status of these cases is shown in
Figure 2 Drug Association Heat Map of Bladder Urothelial Carcinoma Using Caris Molecular Intelligence Recommendation
Based on Biomarker Status and Published Level of Evidence
Highlighted Rows ¼ National Comprehensive Cancer Network Recommendation. Red ¼ Recommendation for Beneﬁt; Gray ¼ Indeterminate; and Blue ¼ Recommendation for Lack of Beneﬁt From
Indicated Therapy
Sherri Z. Millis et ala heat map (Figure 2), revealing that many tumors express positive
and negative predictive biomarkers and therapy associations, an
important consideration in combination therapy.
Biomarkeredrug association beneﬁt is best represented by pa-
tient outcomes. A single case study (Figure 3) provides an example
of a HER2-positive patient treated with an anti-HER2/neu agent,
with associated decrease in mass.
Discussion
Patients with locally advanced or metastatic UC are considered to
have limited targeted therapeutic options. Standard chemotherapy
treatment options are a combination of either methotrexate/
vinblastine/adriamycin/cisplatin, or gemcitabin/cisplatin. Our
multiplatform molecular survey of UC of bladder and nonbladder
origin revealed 43 different therapeutic options across 98% of cases
(based in large part on aberrations in biomarkers PIK3CA, PTEN,
EGFR, HER2, TOPO2a, TOPO1, TUBB3, MGMT, and AR). In
addition to increasing the potential options for therapies eightfoldover standard care options, this approach results in an improvement
in the proportion of cases (22% more) and a doubling in the
number of drugs associated with potential beneﬁt over a recently
published study.15
Our study revealed frequent alterations of PIK3CA (mutations)
and PTEN (protein loss with a few gene mutations) in UC. The
spectrum of PIK3CA mutations differs from that seen in other
cancers.16 The most common PIK3CA mutations (E542K and
E545K) affect the helical domain, and kinase domain mutations
(eg, H1047R) are less common.9,17 Of note, these mutations
also characterize advanced nonurologic malignancies.18 PTEN
loss/inactivation has been implicated in UC development13,16,19-23
and progression24,25 and correlated with the tumor stage and
grade.7,16-17,19 PTEN mutations have been rarely identiﬁed in
bladder UC. The PTEN status ﬁndings in bladder cancer are in line
with the previous studies.3,17,19,25-27 Taken together, our results
indicate that deregulation of the PIK3CA/PTEN axis plays an
important role in a subset of patients with locally advanced orClinical Genitourinary Cancer February 2015 - e41
Figure 3 Chest Scan Images From a 62-Year-Old Female Patient With Metastatic Renal Pelvis Urothelial Carcinoma. The Patient was
Found to be HER2/neu 2D Positive Using Immunohistochemistry and had HER2/neu Ampliﬁcation Using Fluorescence in
Situ Hybridization (Ratio, 4.37). She Therefore Entered a Clinical Trial of Paclitaxel/Trastuzumab With the Investigational
Anti-HER2/neu Agent MM 111. She was Treated With the Agents for 6 Months. These Images from the Chest Computed
Tomography Scan are (A) Baseline and (B) After 2 Months of Therapy
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e42 -metastatic UC that might be responsive to selective PIK3CA/AKT/
mTOR inhibitors (eg, everolimus and temsirolimus).
Of the steroid receptors expression, the highest positivity rate was
observed for AR, which has been correlated to better response to
antiandrogen therapy in prostate, breast, and salivary gland cancers.28-30
AR expression appears to progressively decrease with the tumor stage,31
but we found AR expression in 16% of locally advanced/metastatic UC
of the bladder, suggesting a signiﬁcant potential for tailored therapy with
antiandrogens in this speciﬁc subgroup.
HER2 status has been extensively studied in bladder UC with
heterogeneous results on the frequency of HER2 ampliﬁcation
(range, 0%-42%). The 2 largest studies conducted by Simon et al12
and Lae et al32 showed that the ampliﬁcation rate of HER2 is
approximately 6%. Our study revealed that 12% of inﬁltrating
UCs of the bladder harbored HER2 ampliﬁcation. The markedly
higher HER2 positivity in our study might be because of the pre-
dominantly advanced and metastatic UC we analyzed. Similarly,
Fleischmann et al found substantially greater HER2 positivity (15%)
in metastatic bladder cancers, compared with their primary coun-
terparts (9%).33 In contrast, the nonbladder UC cohort showed a rate
of HER2 positivity (6%) similar to the 2 previous studies.
HER2 ampliﬁcation has been shown to be associated with im-
proved response to HER2-targeted therapy such as trastuzumab,
lapatinib, ado-trastuzumab, and pertuzumab in breast cancer34,35
and advanced gastric/gastroesophageal junction and rectal cancers
(trastuzumab).36,37 Further, HER2 status has been shown to in-
ﬂuence clinical efﬁcacy to anti-EGFR monoclonal antibodies in
patients with metastatic colon cancer.38 These results, along with
the lack of the PIK3CA/PTEN/AKT alterations in most HER2-
positive UCs of the bladder, indicate eligibility in a subset of pa-
tients for targeted therapy with trastuzumab or similar agents
(Figure 3).
Despite the common TOPO2a protein expression in UC,
TOPO2A ampliﬁcation appears to be a rare event.39-41 IncreasedClinical Genitourinary Cancer February 2015expression of TOPO2a protein has been associated with histological
responses and better disease free survival (DFS) to doxorubicin-
based chemotherapy in soft tissue sarcoma patients.42 Even
though TOPO2A was not ampliﬁed in our samples, HER2 over-
expression/ampliﬁcation was noted and the vicinity of TOPO2A
and HER2 genes in chromosome 17q1243; the correlation between
HER2 overexpression and response to anthracycline-containing
therapies might suggest anthracyclines as a potential beneﬁt to
UC patients.
A DNA-repair gene involved in chemotherapy response,
MGMT,44 was commonly coexpressed in EGFR-ampliﬁed UC.
In vivo and early phase clinical trials conﬁrmed a therapeutic beneﬁt
for bladder patients when combined treatment based on EGFR
inhibitors and taxanes was used.5
Expression of TUBB3 has been associated with the tumor
invasiveness, poorly differentiated morphology, and decreased
sensitivity to antitubulin agents such as taxanes and vinca alka-
loids.45 Our results, in line with previous data, indicate a potential
resistance to antitubulin agents in a substantial proportion of UCs,
particularly subsets of small cell carcinomas and adenocarcinomas of
the bladder.
Epidermal growth factor receptor protein expression has been
frequently observed in UC, and EGFR gene alterations were uncom-
mon.46-49 We found EGFR ampliﬁcation in approximately 20% of
bladder and nonbladder UCs. Thirty percent of those with EGFR
ampliﬁcation also harbored aHER2 aberration. Combination therapy
based on coactivation of EGFR and HER2 in a subset of UC of the
bladder might be promising because a previous clinical trial indicated
a potential therapeutic beneﬁt of such an approach in bladder patients
with coactivation of these receptors.5 In addition, the lack of KRAS
alterations in EGFR-positive UC also supports the anti-EGFR thera-
peutic approach, observed in pancreatic cancer patients.50 EGFR
mutations, although rare, as earlier conﬁrmed,11 indicate a potential
lack of response to EGFR tyrosine kinase inhibitors.
Sherri Z. Millis et alAnother potential beneﬁt of biomarker evaluation could be in the
design of clinical trials for advanced UC. In 2 recent studies, re-
sponses to drugs with well-deﬁned predictive biomarkers were
investigated.51,52 The studies could provide new combination
therapies for metastatic UC, but unfortunately, the studies failed to
evaluate molecular status of the patients. Inclusion of the biomarker
status would allow patients to be stratiﬁed based on level of
response.
Conclusion
Comprehensive molecular proﬁling of UC using multiple tech-
nologies has identiﬁed a number of actionable targets that could lead
to individualized therapy using NCCN-recommended and therapies
not currently approved for UC, but approved for other tumor types.
Clinical Practice Points
 Comprehensive molecular proﬁling of inﬁltrating UC might
identify a large number of biomarker aberrations that might
direct treatment using conventional chemotherapies and targeted
therapies, not currently recommended in this population.
 As a group, bladder UCs exhibited higher levels of actionable
biomarkers, suggesting that UCs from different primary sites and
non-UCs are driven by different molecular pathways.
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Supplemental Table 1 Immunohistochemistry
Antibody (Marker) Threshold
Androgen Receptor (AR) ¼ 0þ or <10% or 1þ and 10%
c-Kit (CD117) ¼ 0þ and ¼ 100% or 2þ and 30%
c-MET <50% or <2þ or 2þ and 50%
Estrogen Receptor (ER) ¼ 0þ or <10% or 1þ and 10%
Progesterone Receptor (PR) ¼ 0þ or <10% or 1þ and 10%
Epidermal Growth Factor
Receptor (EGFR)
2þ and 10%
Human Epidermal Growth
Factor Receptor 2 (HER2)
1þ or ¼ 2þ and 10% or
3þ and >10%
O(6)-methylguanine-
methyltransferase (MGMT)
¼ 0þ or 35% or 1þ and >35%
P-Glycoprotein (PGP) ¼ 0þ or <10% or 1þ and 10%
Phosophatase and Tensin
Homolog (PTEN)
¼ 0þ or 50% or 1þ and >50%
Ribonucleotide Reductase
M1 (RRM1)
¼ 0þ or <50% or <2þ or 2þ
and 50%
SPARC (Osteonectin) <30% or <2þ or 2þ and 30%
Transducin-Like Enhancer
of Split 3 (TLE3)
<30% or <2þ or 2þ and 30%
Topoisomerase 2 Alpha
(TOPO2a)
¼ 0þ or <10% or 1þ and 10%
Topoisomerase 1 (TOPO1) ¼ 0þ or <30% or <2þ or 2þ
and 30%
Thymydilate Synthase (TS) ¼ 0þ or 3þ and <10% or 1þ
and 10%
Tubulin b-3 Chain (TUBB3) <30% or <2þ or 2þ and 30%
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Supplemental Table 2 Genes
Gene Approved Symbol Approved Name HGNC ID Location
MPL MPL Myeloproliferative leukemia virus oncogene HGNC:7217 1p34
NRAS NRAS Neuroblastoma RAS viral (v-ras) oncogene homolog HGNC:7989 1p13.2
ALK ALK Anaplastic lymphoma receptor tyrosine kinase HGNC:427 2p23
IDH1 IDH1 Isocitrate dehydrogenase 1 (NADPþ), soluble HGNC:5382 2q32-qter
ERBB4 ERBB4 V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4 HGNC:3432 2q33.3-q34
VHL VHL Von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase HGNC:12687 3p25.3
MLH1 MLH1 MutL homolog 1, colon cancer, nonpolyposis type 2 (E coli ) HGNC:7127 3p22.3
CTNNB1 CTNNB1 Catenin (cadherin-associated protein), beta 1, 88kDa HGNC:2514 3p21
PIK3CA PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha HGNC:8975 3q26.3
KDR KDR Kinase insert domain receptor (a type III receptor tyrosine kinase) HGNC:6307 4q11-q12
KIT KIT V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog HGNC:6342 4q11-q12
FBXW7 FBXW7 F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase HGNC:16712 4q31.23
APC APC Adenomatous polyposis coli HGNC:583 5q21-q22
CSF1R CSF1R Colony stimulating factor 1 receptor HGNC:2433 5q32
PDGFR PDGFRB Platelet-derived growth factor receptor, beta polypeptide HGNC:8804 5q33.1
NPM1 NPM1 Nucleophosmin (nucleolar phosphoprotein B23, numatrin) HGNC:7910 5q35.1
EGFR EGFR Epidermal growth factor receptor HGNC:3236 7p12
MET MET Met proto-oncogene HGNC:7029 7q31
SMO SMO Smoothened, frizzled family receptor HGNC:11119 7q32.1
BRAF BRAF V-raf murine sarcoma viral oncogene homolog B HGNC:1097 7q34
FGFR1 FGFR1 Fibroblast growth factor receptor 1 HGNC:3688 8p12
JAK2 JAK2 Janus kinase 2 HGNC:6192 9p24
ABL1 ABL1 C-abl oncogene 1, non-receptor tyrosine kinase HGNC:76 9q34.1
NOTCH1 NOTCH1 Notch 1 HGNC:7881 9q34.3
RET RET Ret proto-oncogene HGNC:9967 10q11.2
PTEN PTEN Phosphatase and tensin homolog HGNC:9588 10q23
FGFR2 FGFR2 Fibroblast growth factor receptor 2 HGNC:3689 10q25.3-q26
HRAS HRAS Harvey rat sarcoma viral oncogene homolog HGNC:5173 11p15.5
ATM ATM Ataxia telangiectasia mutated HGNC:795 11q22-q23
KRAS KRAS Kirsten rat sarcoma viral oncogene homolog HGNC:6407 12p12.1
PTPN11 PTPN11 Protein tyrosine phosphatase, non-receptor type 11 HGNC:9644 12q24.1
HNF1A HNF1A HNF1 homeobox A HGNC:11621 12q24.31
FLT3 FLT3 Fms-related tyrosine kinase 3 HGNC:3765 13q12
RB1 RB1 Retinoblastoma 1 HGNC:9884 13q14.2
AKT1 AKT1 V-akt murine thymoma viral oncogene homolog 1 HGNC:391 14q32.32-q32.33
CDH1 CDH1 Cadherin 1, type 1, E-cadherin (epithelial) HGNC:1748 16q22.1
TP53 TP53 Tumor protein HGNC:11998 17p13.1
ERBB2 ERBB2 V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 HGNC:3430 17q11.2-q12
SMAD4 SMAD4 SMAD family member 4 HGNC:6770 18q21.1
GNA11 GNA11 Guanine nucleotide binding protein (G protein), alpha 11 (Gq class) HGNC:4379 19p13.3
STK11 STK11 Serine/threonine kinase 11 HGNC:11389 19p13.3
JAK3 JAK3 Janus kinase 3 HGNC:6193 19p13-p12
GNAS GNAS GNAS complex locus HGNC:4392 20q13.2-q13.3
SMARCB1 SMARCB1 SWI/SNF related, matrix associated, actin dependent regulator of chromatin,
subfamily b, member 1
HGNC:11103 22q11.23
Abbreviation: HGNC ID ¼ HUGO Gene Nomenclature Committee unique gene ID.
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Supplemental Table 3 Frequency and Types of Mutations Detected in Urinary Bladder Carcinomas
Gene Number P PP VUS
APC 2 2
K1454E 1
A1474T 1
BRAF 1 1
G469Aa 1 1
CDH1 3 3
D400N 1 1
D402G 1 1
D402H 1 1
c-MET 1 1
T1010I 1 1
EGFR 3 3
H773dupa 1 1
770D_771NinsG 1 1
G719S 1 1
ERBB2 1 1
D769H 1 1
FBXW7 2 2
R465L 1 1
R479G 1 1
FGFR3 3
F384L 1
S249C 2
KDR 1 1
D1313H 1 1
c-KIT 1 1
G565Va 1 1
KRAS 5 5
G12V 2 2
G12Aa 1 1
G12Ra 1 1
G12Sa 1 1
PIK3CA 19 17 2
E545K (7a) 9 9
E542Ka 3 3
H1047R (1)a 2 2
Q546La 2 2
Q546R 1 1
R88Q 2 2
PTEN 4 3 1
L247fs 1 1
R172S 1 1
T319X 1 1
Y68H 1 1
RB1 2 2
D571N 1 1
Y692C 1 1
SMAD4 1 1
T174N 1 1
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Supplemental Table 3 Continued
Gene Number P PP VUS
STK11 1 1
F354L 1 1
TP53 23 17 5 1
D281N 1 1
E171X 1 1
E198X 1 1
E271fs 1 1
E271K 1 1
E298X 1 1
N239S 1 1
P177L 1 1
Q192X 1 1
R158H 1 1
R175H 2 2
R196X 2 2
R213P 1 1
R248Q 2 2
R248W 2 2
R306X 1 1
S183X 2 2
S241F 1 1
Abbreviations: P ¼ pathogenic; PP ¼ presumed pathogenic; VUS ¼ variant of unknown signiﬁcance.
aIndicates identiﬁed by Sanger sequencing.
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Supplemental Table 4 Mutation Frequency Proﬁle of Different Subtypes of Nonurothelial Bladder Carcinoma
Gene Small-Cell Carcinoma Squamous Cell Carcinoma Adenocarcinoma
APC 0/4 0/1 0/5
BRAF 0/9 0/3 0/7
CDH1 0/4 0/1 0/5
c-KIT 0/9 0/1 0/6
c-MET 0/4 0/1 0/5
EGFR 1/5 (20%; G719S) 0/1 0/5
ERBB2 0/4 0/1 0/5
FBXW7 0/4 0/1 0/5
FGFR3 0/3 0/1 0
HNF1A 0/2 0/1 0/4
HRAS 0/4 0/1 0/5
KDR 0/4 0/1 0/5
KRAS 0/11 0/3 5/9 (55.6%)a
PIK3CA 0/8 0/3 1/8 (12.5%)
PTEN 0/4 0/1 0/5
RB1 0/4 0/1 0/5
SMAD4 0/4 0/1 0/5
STK11 0/4 0/1 0/5
TP53 4/4 (100%) 0/1 1/4 (25%)
aP < .001 (compared with bladder urothelial carcinoma).
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